GDF15 and the beneficial actions of metformin in pre-diabetes
By
Anthony P Coll,
Michael Chen,
Pranali Taskar,
Debra Rimmington,
Satish Patel,
John Tadross,
Irene Cimino,
Ming Yang,
Paul Welsh,
Samuel Virtue,
Deborah A Goldspink,
Emily Miedzybrodzka,
Y. C. Loraine Tung,
Sergio Rodriguez-Cuenca,
Rute A. Tomaz,
Heather P Harding,
Audrey Melvin,
GSH Yeo,
David Preiss,
Antonio Vidal-Puig,
Ludovic Vallier,
David Ron,
Fiona M. Gribble,
Frank Reimann,
Naveed Sattar,
David B Savage,
Bernard B Allan,
S O’Rahilly
Posted 21 Jun 2019
bioRxiv DOI: 10.1101/677831
(published DOI: 10.1038/s41586-019-1911-y)
Metformin, the world's most prescribed anti-diabetic drug, is also effective in preventing Type 2 diabetes in people at high risk, by lowering body weight, fat mass and circulating insulin levels through mechanisms that are incompletely understood. Recent observational studies reporting the association of metformin use and circulating levels of GDF15 led us to hypothesize that GDF15, which signals through a specific receptor complex in the hindbrain to reduce body weight, might mediate these effects. We measured GDF15 in people without diabetes from a randomized placebo-controlled trial of metformin. Over 18 months, participants allocated metformin lost significant weight and levels of GDF15 were persistently elevated compared to placebo. The change in plasma GDF15 in this study correlated positively with weight loss. In wild-type mice, oral metformin increased circulating GDF15 with GDF15 expression increasing predominantly in the distal intestine and the kidney. Metformin prevented weight gain in response to high fat diet in wild-type mice but not in mice lacking GDF15 or its receptor GFRAL. In obese, high fat-fed mice, the effects of metformin to reduce body weight were reversed by a GFRAL antagonist antibody. Metformin had effects on both energy intake and energy expenditure that required GDF15. The insulin sensitising effects of metformin determined by insulin tolerance were abolished in mice lacking GDF15. Metformin significantly reduced fasting glucose and insulin levels in wild type but not in mice lacking GDF15. In summary, metformin increases the circulating levels of GDF15, which appears to be necessary for many of its actions as a metabolic chemopreventive agent.
Download data
- Downloaded 1,291 times
- Download rankings, all-time:
- Site-wide: 13,322
- In physiology: 31
- Year to date:
- Site-wide: 54,436
- Since beginning of last month:
- Site-wide: 54,436
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!